CBD for asthma and the respiratory system: can cannabidiol alleviate symptoms

Asthma is one of the most common chronic diseases of the respiratory system — it affects about 300 million people worldwide and 3–4 million Poles. Despite the availability of inhaled medications, some patients seek natural methods of support. CBD is increasingly appearing in this discussion — and there are indeed biological grounds to believe that cannabidiol may have beneficial effects on the respiratory system. However, there are also several absolute contraindications: smoking cannabis with asthma is one of the worst ideas one can have. In this article, we will discuss the mechanisms, research data, appropriate routes of administration, and interactions with pulmonary medications.

KEY INFORMATION
• Vuolo et al. (British Journal of Pharmacology, 2019) demonstrated a reduction in airway inflammation by CBD in a mouse model of allergic asthma.
• CB1 and CB2 receptors in the lungs regulate bronchial tone, mucus secretion, and the inflammatory response — CBD modulates these pathways.
• In asthma, CBD can only be used orally or sublingually — smoking and vaping are absolutely contraindicated.
• CBD does not replace inhaled corticosteroids (ICS) or LABA — it is a potential supportive supplement, not a medication.

The endocannabinoid system in the lungs – biological basis

Cannabinoid receptors CB1 and CB2 are present in the tissues of the respiratory system — in the smooth muscles of the bronchi, the epithelium of the airways, and the immune cells of the lungs (macrophages, mast cells). This means that the endocannabinoid system is actively involved in regulating respiratory functions and can be modulated by CBD.

CB1 receptors in the smooth muscles of the bronchi: their activation leads to relaxation (bronchodilation) — a desired effect in asthma, where contraction of smooth muscles causes narrowing of the airways. Endogenous anandamide activates CB1, inducing bronchodilation. CBD indirectly enhances this effect by inhibiting the breakdown of anandamide by the FAAH enzyme. CB2 receptors in mast cells: their activation inhibits degranulation, which is the release of histamine and leukotrienes during an allergic reaction. This could be a mechanism by which CBD limits the allergic component of asthma.

An additional mechanism: CBD inhibits TRPV1 (vanilloid) receptors in the epithelium of the airways — these receptors are strongly activated by irritants (smoke, pollen, cold air) and contribute to bronchial hyperreactivity. Their desensitization by CBD may potentially reduce this hyperreactivity. Vuolo i wsp. (British Journal of Pharmacology, 2019) they discussed these mechanisms and demonstrated a reduction in inflammatory markers in the airways of mice with allergic asthma after administering CBD.

Scientific research – what do we know about CBD and the respiratory system?

Key study on CBD and asthma — Vuolo i wsp. (British Journal of Pharmacology, 2019) — is a study on a mouse model of allergic asthma. Mice sensitized to OVA (ovalbumin) and exposed to allergen inhalation exhibited typical features of asthma: eosinophilic inflammation, mucus overproduction, and airway remodeling. Administration of CBD reduced the influx of eosinophils to the lungs by about 30%, lowered levels of IL-5 and IL-13 (cytokines crucial for the Th2 response in asthma), and decreased mucus production. The results are biologically interesting — but they pertained to mice, not humans, and cannot be directly translated into clinical practice.

Previous studies on the endocannabinoid system and bronchi — a review Borrelli i Izzo (British Journal of Pharmacology, 2009) — indicated that CB1 agonist cannabinoids caused bronchodilation in in vitro and in vivo models, while CB1 antagonists exacerbated bronchoconstriction. This suggests that the endocannabinoid pathway is physiologically significant for regulating bronchial tone.

Unfortunately: we do not have large, randomized clinical studies in humans with asthma using CBD. The clinical literature is limited to a few small pilot studies and observations. This does not allow for conclusions about the efficacy of CBD in asthma in humans at the level of evidence-based medicine.

Why smoking and vaping cannabis are prohibited in asthma

This is a fundamental principle that cannot be overlooked. Smoking anything — cigarettes, cannabis, CBD flower — causes immediate irritation of the bronchial epithelium, triggers bronchoconstriction, and is one of the strongest triggers of an asthma attack. For a person with asthma, inhaling smoke is not an "alternative route of CBD administration" — it is a potentially life-threatening provocation of the bronchi.

Vaping CBD (e-cigarettes with CBD oil, vape pens) is significantly less harmful than smoking, as it does not produce combustion smoke. However, it is not safe for asthma: the aerosol from vaping devices contains particulate matter and chemical compounds (propylene glycol, vegetable glycerin, potential contaminants) that can irritate hyperreactive airways. Moreover, the EVALI epidemic (E-cigarette or Vaping product use-Associated Lung Injury) of 2019 showed that even 'legal' vaping products can cause serious lung damage.

In the case of asthma, CBD can only be used orally or sublingually. This is not a choice — it is the absolute minimum for safety. Any other method of administration is contraindicated, without exceptions.

Interactions with pulmonary medications – what to check

People with asthma most commonly use one or several of the following medications: inhaled corticosteroids (ICS — budesonide, fluticasone, beclometasone), long-acting beta-2 agonists (LABA — formoterol, salmeterol), short-acting beta-2 agonists (SABA — salbutamol, fenoterol), theophylline and its derivatives (methylxanthine derivatives), montelukast (leukotriene receptor antagonist), anti-IL-5 biologics (mepolizumab, benralizumab).

The good news: inhaled corticosteroids and beta-2 agonists act mainly locally in the lungs and are partially metabolized in the bronchi — the potential for interaction with oral CBD through CYP3A4 is relatively low, although not zero at higher doses of CBD.

Significant interaction: theophylline. Theophylline is metabolized by CYP1A2 — CBD has less impact on this enzyme than on CYP3A4, but at higher doses of CBD, there may be an increase in theophylline concentration. Theophylline has a narrow therapeutic window — a small change in concentration can cause heart arrhythmias, nausea, and seizures. With theophylline, CBD is risky without monitoring concentrations.

Our observations: Asthmatics interested in CBD often ask about 'CBD inhalers' as an alternative to ICS medications. This is a fundamental misunderstanding. CBD does not inhibit IgE synthesis, does not reduce the persistently declining eosinophilic inflammation, and does not improve bronchial remodeling like ICS with long-term use. Even if CBD had a beneficial anti-inflammatory effect in asthma — it would be a complementary effect to ICS, not a replacement. Discontinuing ICS in favor of CBD without a pulmonologist's consent is a straightforward path to uncontrolled asthma and potentially life-threatening attacks.

Stress as an asthma trigger – the indirect role of CBD

Asthma has a well-documented psychosomatic component — emotional stress is one of the classic triggers for attacks in many patients. The mechanism is multifaceted: stress activates the HPA axis, increases the release of corticotropin and cortisol, which paradoxically can increase bronchial hyperreactivity. Stress also activates the sympathetic nervous system, which in asthmatics can exacerbate bronchoconstriction. Finally — stress increases the expression of pro-inflammatory cytokines, including IL-6 and TNF-α, which affect airway inflammation.

In this context, CBD may have an indirect value in stress-induced asthma. By modulating 5-HT1A receptors and the HPA axis, CBD reduces the stress reactivity of the nervous system — which may secondarily reduce the frequency of stress-induced attacks. This is not 'CBD cures asthma' — it is 'CBD reduces one of the triggers for attacks in susceptible individuals.' The difference is crucial for setting proper expectations.

If your asthma attacks are clearly related to stress (e.g., worsening before important events, in conflict situations), reducing stress reactivity through CBD may be clinically sensible — as a supplement to treatment, not a replacement. Discuss this relationship with the pulmonologist or allergist managing your asthma.

Allergens, the immune system, and CBD – what does immunology say?

Allergic asthma (the most common form, about 80% of cases) is driven by the Th2 immune response: sensitization to allergens (pollen, dust mites, pet dander), production of IgE, activation of mast cells, and release of inflammatory mediators. CBD affects several of these pathways.

Mast cells expose CB2 receptors — their activation by cannabinoids suppresses degranulation (release of histamine and leukotrienes). CBD may achieve this effect indirectly by inhibiting FAAH and increasing anandamide. Borrelli i Izzo (BJP, 2009) They described the inhibition of mast cell degranulation by cannabinoids as a biologically significant anti-allergic mechanism. Eosinophils — key cells in asthmatic inflammation — reduce activity when exposed to CBD in in vitro models. The reduction of eosinophil influx by CBD demonstrated by Vuolo et al. (2019) in a mouse model may work through this mechanism.

Does this translate into a clinical reduction in allergies? We cannot determine this without clinical studies. However, the biological consistency of the mechanisms is sufficient to suggest that clinical studies of CBD in allergic asthma make scientific sense and should be conducted. More about CBD and allergic reactions in the article. CBD na alergie.

CBD and chronic bronchitis and COPD – briefly.

Asthma is not the only obstructive respiratory disease. Chronic obstructive pulmonary disease (COPD) and chronic bronchitis are other conditions where CBD is considered. The data is even more limited than with asthma — there are no clinical studies of CBD in COPD. Mechanistically: the anti-inflammatory properties of CBD could be beneficial, and bronchodilatory properties (through CB1) potentially helpful. However, in COPD, most patients have permanently reduced lung function due to parenchymal destruction — CBD cannot reverse this process.

Key principle for COPD: smoking cannabis (even for "therapeutic" purposes) is one of the worst possible actions for a patient with COPD — even a single exposure to cannabis smoke can trigger exacerbation, hospitalization, and accelerate disease progression. CBD in COPD may only be considered in oral form and after consultation with a pulmonologist.

Additional information about CBD in the context of immunity and the respiratory system can be found in the article. CBD and immunity.

Practical tips for asthmatics considering CBD.

If you are an asthmatic and want to consider CBD supplementation, here is a sequence of steps that increases safety. Step one: talk to your attending pulmonologist — inform them of your interest in CBD, ask about potential interactions with current pharmacotherapy (especially with theophylline), and obtain clear consent or prohibition for use.

Step two: if the doctor has no objections — choose a CBD oil for oral or sublingual use. Never inhaled. Start with the lowest dose (5 mg) for the first 3–5 days, observing both the subjective effect and any changes in respiratory function (discomfort, worsening of asthmatic symptoms).

Step three: monitor peak expiratory flow (PEF) — if you have a peak flow meter, use it regularly for the first 2–4 weeks of CBD use to catch any potential deterioration in lung function. Any worsening of PEF or worsening of symptoms is a signal to discontinue CBD and consult.

Step five: keep a symptom diary. Note daily: the number of uses of the rescue inhaler (SABA), sleep quality, subjective respiratory discomfort, and PEF result. Compare weeks with CBD and without CBD after a few weeks. This is the only method to assess individual response to CBD in a condition as variable and multifactorial as asthma. Without systematic notes, you will not be able to determine if CBD made any difference.

Step four: do not change your asthma treatment plan without medical consent — do not reduce the ICS dose, do not skip the rescue SABA dose during an attack. CBD does not prevent an acute asthma attack — the SABA inhaler (salbutamol) does. Always keep the blue inhaler with you, regardless of CBD. More about CBD in allergies in the article. CBD na alergie.

Frequently Asked Questions

What to avoid with asthma and CBD?

Absolutely avoid: smoking or vaping CBD cannabis with asthma (the most dangerous mistake), discontinuing ICS without a pulmonologist's consent, using CBD with theophylline without monitoring drug levels, buying CBD products without a COA certificate (contaminants can irritate the airways). During any asthma attack — use the SABA inhaler, not CBD oil. The rescue inhaler is irreplaceable.

Does CBD help with asthma?

Preclinical data is promising — Vuolo i wsp. (British Journal of Pharmacology, 2019) they demonstrated a reduction in airway inflammation by CBD in a mouse model of allergic asthma. There are very few clinical studies in humans. CBD is not an approved treatment for asthma and does not replace ICS or LABA.

Can CBD be smoked or inhaled with asthma?

Definitely not. Smoking anything is one of the strongest triggers for an asthma attack and causes permanent damage to the bronchial epithelium. Vaping is less harmful, but still irritates hyperreactive airways. With asthma, CBD is only for oral or sublingual use.

How does CBD affect the respiratory system?

CBD modulates CB1 receptors (bronchodilation through smooth muscles), CB2 (inhibition of mast cell degranulation), and TRPV1 (desensitization, reduction of hyperreactivity) in lung tissues. It also inhibits Th2 cytokines (IL-5, IL-13) involved in allergic asthma — according to Vuolo i wsp., 2019.

Does CBD interact with asthma medications?

Theophylline — yes: CBD may increase its concentration, which is dangerous with a narrow therapeutic window. Inhaled ICS and beta-2 agonists — potential for interaction is low, but present. Consultation with a pulmonologist before starting CBD with asthma pharmacotherapy is mandatory.

What doses of CBD were used in studies on the respiratory system?

Clinical studies in humans with CBD and asthma are still very limited. The data from Vuolo et al. was based on animal models. For supplementation in adults with asthma, typical doses of 10–30 mg/day are described in observational literature, without confirmation in RCT.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult with a physician, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04